The triggering receptor expressed on myeloid cells 2 (TREM2) plays a pivotal role in the activation of myeloid cells and is currently being investigated as a potential therapeutic target in several ...

Currently, PET scanner validation phantoms, methods, and acceptance criteria for clinical trials are not standardized. This ...

Whole-body CD8+ T-cell PET imaging can detect spatial and temporal localization of CD8+ T cells. To obtain insight into early CD8+ T-cell response to immunotherapy in patients with melanoma, a highly ...

Foregoing Nonclinical Dosimetry Studies to Support First-in-Human Studies of Certain PET Radiopharmaceuticals ...

REPLY: In our recent letter to the editor, we discussed the evolving preclinical testing requirements for PET drugs at the Food and Drug Administration (FDA) ([1][1]). In particular, we highlighted ...

Current methods for evaluating HER2 expression in breast cancer are invasive and fail to capture spatial and temporal heterogeneity between primary tumors and metastases. Nuclear imaging allows for ...

The PSMA-PET Registry for Recurrent Prostate Cancer study was initiated in Ontario, Canada, to provide access to and characterize the performance of 18F-prostate-specific membrane antigen (PSMA) ...

Fibroblast activation protein (FAP) has become an attractive target for diagnosis and therapy, and a series of FAP inhibitor (FAPI) based radiotracers have been developed and performed excellent ...

With the increasing use of radiopharmaceutical therapies, there is a critical need to appropriately inform health care professionals (HCPs) who are unfamiliar with these therapies about the radiation ...

Nuclear medicine has evolved from a diagnostic-oriented speciality toward theranostics. Radionuclide therapy has become a booming business with newer radiopharmaceuticals and indications. Although the ...

In recent years, there has been a headlong rush into the use of prostate-specific membrane antigen (PSMA)–targeted PET for the staging and restaging of men with prostate cancer (PC). To date, there ...